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‘EUROPE OF PATIENTS, EUROPE FOR PATIENTS’: THE 
EUROPEANIZATION OF HEALTHCARE POLICIES BY EUROPEAN 
PATIENTS’ ORGANIZATIONS 
Vololona Rabeharisoa* and Orla O’Donovan** 
 
Introduction 
The last two decades have witnessed an efflorescence of European lobbying 
organizations, including European civil society organizations (Lahusen 2004). 
Lobbying activity is mainly clustered around enterprise and environmental 
policy, domains in which the EU has greatest regulatory competencies. 
However, health has been identified as the fastest growing lobbying sector 
(Coen 2007). Patients’ organizations have been part of the ‘rush to Europe’. 
This domain is of particular significance because healthcare is a major area of 
the welfare state in which the EU has in the past had little involvement, but one 
which has in recent years witnessed an increasing Europeanization of policy 
(Greer et al. 2008). To date, very few studies have explored the species of 
organizations that European patients’ organizations (EPOs) constitute, and the 
form of activism they develop. This article examines these two issues. 
The notion of Europeanization has raised substantial discussion over the 
past years. For political scientists, Europeanization designates a process 
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different from European integration (Featherstone and Radaelli 2003): 
European integration pertains to nation states transferring part of their 
sovereignty to a supranational authority, whereas Europeanization consists in 
the adaptation of domestic institutions and policies to this system once 
constituted. A large body of the literature on this process of ‘societal 
transformation, pointing to a reconfiguration of cultures, identities and forms of 
governance’ (Sassatelli 2008: 225) focuses on the role played by the EU, either 
by exerting pressures through its rules and procedures (Radaelli 2003), or by 
promoting European policies (Shore 1993). Studies also examine the 
opportunities offered by the very existence of the EU to Member States for 
reorienting their own domestic policies (Putman 1998). Recently, however, 
research on the role of civil society organizations (CSOs) in the process of 
Europeanization has blossomed. Della Porta and Caiani’s (2007) examination 
of ‘Europeanization from below’ stands as a remarkable contribution. 
Della Porta and Caiani (2009: 25) define Europeanization from below as 
Europeanization of and by civil society. They identify two paths whereby CSOs, 
and notably social movement organizations (SMOs), Europeanize their claims 
and frames, the paths of ‘domestication’ and ‘externalization’; the first refers to 
the targeting of national governments by SMOs to address EU issues, and the 
second to the targeting of EU institutions in efforts to pressurize them to 
intervene at national level. In cases of ‘externalization’, SMOs also ‘go to 
Europe’ to engage in a process of supranational network formation that cannot 
be done nationally (Montforte, 2009). 
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Della Porta and Caiani (2009) also discuss extensively the promises of 
Europeanization by civil society, especially democratizing Europe. Both pull and 
push dynamics drive CSOs to Brussels, as CSOs push their way into the newly 
opening channels of influence, but are also pulled in by EU institutions in search 
of democratic legitimacy (Putman 1998; Dunkerley and Fudge 2004). Della 
Porta and Caiani emphasize SMOs’ potential contribution to the emergence of a 
truly European public sphere and a European demos. Establishing a ‘social 
Europe’ as an alternative to the ‘Europe of markets’ is another promise of 
Europeanization from below. Much analysis of CSOs (Bieler 2007; Storey 2008) 
focuses on how they might resist the neoliberal nature of the current European 
project manifested in the reliance on ‘hard law’1 for competition and other 
economic policies, and ‘soft law’2 for policies to defend and extend a ‘social 
Europe’. 
This article considers how EPOs contribute to Europeanization from below 
and its promises. Based on an analysis of the projects, pronouncements and 
politics of three EPOs – EURORDIS (European Organization on Rare 
Diseases), Alzheimer Europe, and ADHD Europe (Attention Deficit Hyperactivity 
Disorder) –, we investigate their role in the Europeanization of patient 
advocacy, moving it beyond national level organizing and acting. We also 
explore EPOs’ role in Europeanization by patient advocacy, their contribution to 
debates and policies on healthcare at European level. Our argument is that 
                                            
1 ‘Hard law’ mainly designates the corpus of EU directives and regulation that Member States 
must comply with. 
2 ‘Soft law’ procedures include a variety of instruments whereby EU acts as a policy-coordinator 
between Member States. We discuss some of these instruments later on. 
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Europeanization from below does not consist merely of bringing national claims 
up to the European level, nor simply enriching national debates with EU issues. 
Crucially, it also entails a compounded multilevel process whereby EPOs give 
shape to health issues they deem important to address at European level, and 
build European communities of patients. This approach, which echoes Delanty 
and Rumford’s (2005) questioning on the construction of Europe, is particularly 
relevant here. Indeed, healthcare remains the preserve of Member States, 
which implies that EPOs have to form European communities of patients and 
define the causes they stand for as European for them to effectively and 
meaningfully act at European level. This is what we show in the first section, 
drawing on interviews with representatives and staff members of these 
organizations, website and document analysis, workshops, conferences and 
events that they organized over the three year duration of our research project. 
In the second section, we turn to the forms of activism that EPOs develop and 
the Europe for patients to which they give rise. We highlight their intensive 
activity for producing facts, statistics and indicators in order to calibrate and 
justify their intervention at the crossroads of the ‘Europe of markets’ and a 
‘social Europe’. This ‘evidence-based activism’, as we may call it, points to the 
importance of metrological activity for the making of Europe, as Barry (2001) 
has demonstrated. In the conclusion, we revert to the promises of 
Europeanization from below and if and how they are advanced by EPOs. 
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1. European patients’ organizations and the construction of a Europe of 
patients: from the ‘patient-consumer’ to the ‘patient-sufferer’ 
For the EPOs we studied, building communities of patients and raising their 
capacity to act at European level are strategic missions. Indeed, the patient, as 
an individual with a disease, is not an ordinary European subject. This is due to 
the historical constitution of European patients as consumers.  
Historically, the prerogatives of the EU were confined to the establishment 
and regulation of the European Single Market, whereas the principle of 
subsidiarity applied, and still applies, to sectors such as education and health. 
As far as health is concerned, Europe intervenes largely as a rule-maker in the 
health market, for example in the regulation of drug and private health 
insurance markets and legislation on the safety of bio-products. From the 
perspective of the European constitution, health is a sector of production, 
circulation and consumption of health-related goods and services. This is 
manifested in the title of DG SANCO – Directorate General for Health and 
Consumers (our emphasis) –, as well as in the first European initiatives in the 
domain of healthcare. 
Jarman and Greer recall (2010) that these initiatives began in 1998 with 
rulings made by the European Court of Justice that healthcare activities are 
services subject to the EU’s laws on the internal market. In an effort to legislate 
for the incorporation of healthcare into the general EU regime for the regulation 
of services, in 2004 the European Commission proposed the controversial 
Bolkestein Directive. Cited as an example of the ‘externalization’ path of 
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Europeanization of SMOs, Della Porta and Caiani (2009: 83) describe how the 
Directive was opposed trenchantly by many SMOs as ‘an atrocious attack on 
public services, workers’ rights and democracy’, beginning with opposition at 
the national level and extending to European SMOs, networks and coalitions. 
Forced to abandon the Bolkestein Directive, a revised European Directive on 
patients’ rights to cross-border healthcare that moved away from promoting 
trade in services to ostensibly promoting citizens’ rights was put under the co-
decision of the European Council and the European Parliament and passed in 
2009, while the principle of subsidiarity continues to apply to the sector of 
healthcare. 
In parallel to these regulations, soft law instruments were formalized over the 
Convention working groups that resulted in the Lisbon Treaty in 2000. Amongst 
those instruments, OMC (Open Method of Coordination) emerged as one major 
tool for fostering European construction in areas where Europe’s initiatives were 
heretofore restricted. OMC draws on procedures that permit multilevel 
governance on issues for which Europe does not act as a rule-maker but rather 
as a policy-coordinator. It consists in: 
‘(…) fixing guidelines for the Union combined with specific time-tables for 
achieving goals (…) in the short, medium and long terms; establishing, 
where appropriate, quantitative and qualitative indicators and benchmarks 
against the best in the world and tailored to the needs of different Member 
States and sectors as means of comparing best practices; translating these 
European guidelines into national and regional policies by setting specific 
targets; periodic monitoring, evaluation and peer review organized as 
 7
mutual learning processes’. (Presidency Conclusions, Lisbon European 
Council, 23-24 March 2000, Point 37) 
 OMC certainly paved the way for European actions in the sector of 
healthcare, such as the Europe for Patients Campaign launched by DG SANCO 
in 2008 as part of the European Health Programme 2008-2013. For the first 
time in European history, healthcare for patients with specific diseases, notably 
Alzheimer’s disease and rare diseases, were featured amongst the eleven 
priorities of this programme. This programme de facto profiled a new figure of 
the patient as an individual suffering from a given condition. It is this nascent 
figure of the ‘patient-sufferer’, in contrast to the historic ‘patient-consumer’ and 
the abstract ‘patient-citizen’ that EPOs give rise to and consolidate. 
Indeed, the EPOs we studied formed with an aim to gather European 
patients and to voice their concerns at European level. This however does not 
merely consist of grouping existing national patients’ groups and pooling their 
claims at European level. Each EPO had to simultaneously give shape to a 
transnational community of patients, and define the disease or condition they 
are concerned with as a relevant European issue. Depending on how it 
formulated the cause it stands for at European level, each EPO adopted a 
configuration and a representational scheme it deemed appropriate and thus 
Europeanized in different ways. 
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1.1. Alzheimer Europe: representational monopoly and the scaling up of political 
advocacy 
Alzheimer Europe holds a classical status of European advocacy group. It 
resembles many CSOs that Warleigh (2001: 622) describes as having 
Europeanized instrumentally ‘to secure their objectives or in response to 
enticements by the Commission, rather than out of “European” zeal’. When it 
formed in 1990, Alzheimer’s disease (AD) was already considered a major 
challenge for Western societies. At that time, national AD organizations existed, 
some of them for up to a decade. However, although AD was recognized as a 
critical health issue and benefited from effective national activism, it was not an 
object of specific policies articulating research, prevention, care and support to 
patients and carers in all European countries. Alzheimer Europe was created by 
ten AD national organizations for motivating European engagement with AD in 
order to foster national public health policies. 
This scaling up of political advocacy was narrated in a presentation at the 
2010 Alzheimer Europe annual conference entitled ‘Alzheimer Europe 1990-
2010. Celebrating twenty years of achievements’3. Recounting the origin story 
of the European coalition of Alzheimer’s disease patients’ organizations4, the 
Executive Director cited the statement below made in 1990 by the founders of 
Alzheimer Europe: 
                                            
3 Notes from ethnographic observation of the 20th Alzheimer Europe Conference, ‘Facing 
Dementia Together’, 30 September – 2 October 2010, Luxembourg. 
4 The slides for this presentation are available on http://www.alzheimer-europe.org/ 
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‘Because we are all satisfied that we will benefit from European co-
operation, and together can put more pressure on the European Council, 
Commission, Parliament and other national and supranational 
organizations, we have decided to form a European Alzheimer 
organization’. 
In line with this objective, it has expanded the number of member national 
AD organizations and positions itself as their unique legitimate and competent 
interlocutory representative vis-à-vis European institutions. Alzheimer Europe 
strongly emphasizes its representational capacity and monopoly. It publicly 
identifies itself as a European platform and umbrella organization of 34 
Alzheimer associations from 30 countries (including non-EU Member States 
Iceland, Norway, Switzerland and Turkey) which is: 
‘[…] the only organization which is both representative on a European level 
and able to provide a voice for people with dementia and their carers5’. 
1.2. EURORDIS: heterarchical organization and the ‘politics of numbers’ 
EURORDIS shares similar features with Alzheimer Europe: they both have 
professional staff (27 for EURORDIS, 6 for Alzheimer Europe), substantial 
budgets (close to €3 million for EURORDIS, €0.7 million for Alzheimer Europe 
in 2009, to which the European Commission contributes), as well as 
headquarters at strategic locations (Brussels and Paris for EURORDIS, 
Luxembourg for Alzheimer Europe). However, EURORDIS, unlike Alzheimer 
Europe, has a heterarchical organization (Stark 2009) that is uncommon in the 
                                            
5 Alzheimer Europe’s Strategic Plan 2006-2010. See http://www.alzheimer-europe.org/ 
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landscape of EPOs. It has member organizations, but it also welcomes 
individuals who are not affiliated to any patients’ group. Formed in 1997 by 
members of four French patients’ organizations6, EURORDIS aims at 
constituting war on rare diseases as a European cause. Its Executive Director 
explained7 that the organization defined ‘the concept of rare diseases’8 to 
demonstrate that its cause is even more relevant and legitimate at European 
level than at national level. The ‘concept of rare diseases’ denotes a series of 
characteristics shared by these conditions:  they are numerous and all 
different9; some of them concern very few individuals who are either isolated or 
join organizations that are not primarily concerned with their particular disease; 
their prevalence varies from one country to another; expertise is unevenly 
distributed, if not lacking; specialists, when they exist, organize themselves 
differently in each country. 
This ‘concept of rare diseases’ prompted EURORDIS to develop what we call 
a ‘politics of numbers’. EURORDIS summarizes this ‘politics of numbers’ in its 
motto: ‘Rare diseases are rare, but rare diseases patients are many’. The 
organization estimates the number of individuals affected by rare diseases in 
Europe at 30 million. This translates into EURORDIS’ first mission: building a 
                                            
6 With the active support of an official from the French Health Department who had been long 
involved in rare diseases affairs. 
7 Interview with the Executive Director of EURORDIS. 
8 This concept is delineated in a 14 page-statement published by EURORDIS in 2005, entitled: 
‘Rare Diseases: Understanding this Public Health Priority.’ 
http://www.eurordis.org/sites/default/files/publications/princeps_document-EN.pdf 
9 Rare diseases have prevalence lower than 1/2,000 or 5/10,000. To date, close to 6,000 rare 
diseases have been recorded in the world. 80% of them are of genetic origin. 
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community of European individuals and families and becoming ‘The Voice of 
Rare Diseases Patients in Europe’. 
Today, EURORDIS publicly identifies as a non-governmental patient-driven 
organization with 479 member organizations in 45 countries, including non-
European countries. It actively contributes to the creation of National Alliances 
on Rare Diseases, which are statutory bodies of EURORDIS. Most importantly, 
individual patients who have either decided not to belong to any particular 
organization, or whose disease is not represented by any organization, receive 
full membership of EURORDIS if they apply. In addition, a few years ago 
EURORDIS started to build web-based communities of patients around 
diseases.  Additionally, individual patients and families are invited to offer 
testimonies during conferences and workshops, including during institutional 
events like the Rare Disease Day held in Brussels on 1 March 201010. The 
Executive Director of EURORDIS considers11 that the organization is not 
content to be a conventional federation of federations: the individual patient, 
whatever his/her situation, counts, he says, if EURORDIS’ s politics of numbers 
is to be credible. 
1.3. ADHD Europe: mutual recognition between families and ‘politics of 
experience’ 
Like EURORDIS, ADHD Europe has engaged in long-lasting work to legitimate 
ADHD as a relevant cause for Europe. However, whereas EURORDIS’ 
                                            
10 Notes from ethnographic observation of Rare Disease Day ‘Bridging Patients and 
Researchers to Build the Future Agenda for Rare Disease Research in Europe’, 1 March 2010, 
Brussels. 
11 Interview with the Executive Director of EURORDIS. 
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preoccupation was to gain recognition for rare diseases as a major public health 
issue, ADHD Europe had first to state the fact of ADHD over the eight years 
prior to its official creation in 2008. ADHD is one of those unsettled conditions 
that Dumit (2006) called ‘illnesses you have to fight to get’. ADHD still divides 
clinicians in terms of its etiology and appropriate therapeutic intervention. Often 
considered the result of bad parenting, the status of ADHD as a serious 
condition remains contested in many countries. In addition to stigmatization of 
children with ADHD, this situation led to the absence of appropriate care. These 
statements were at the origin of ADHD Europe. 
In 2000, a mother of a child with ADHD living in Belgium recognized a need 
for greater awareness of, and services for, children with the condition. 
Acknowledging the dire provision for children with ADHD in schools in Belgium, 
‘she set out to find out what it was like in the rest of Europe.’12 As the Board 
member we interviewed explained, ‘she got into talks with a colleague in the 
European Commission who had the same experience, because both he and his 
son had ADHD’. The mother applied for funding from the European Commission 
Department of Social Affairs for a project called ‘Knowing Me, Knowing You’. 
Running from 2000 to 2002, the project aimed to map experiences of people 
with ADHD across Europe, and explore the needs of national organizations. Not 
yet formed as ADHD Europe, ‘Knowing Me, Knowing You’ seemed to act as a 
springboard for the emergence of national groups and a growing European 
consciousness on the issue drawing primarily on the lay expertise of parents of 
children with ADHD. At a seminar as part of the project in Copenhagen in 
                                            
12 Interview with a Board member of ADHD Europe, 13 October 2010. 
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November 2001, parents came together to share their experiences of living with 
ADHD. This ‘politics of experience’ was instrumental in stating ADHD as a 
European condition that deserved coordinated action, as a press release on the 
event encapsulated in the following statement: ‘There are no borders in Europe 
concerning ADHD13’. 
1.4. What Europe of patients do EPOs build? 
For EPOs, the dual ontological construction14 of communities of patients as 
European collectives, and conditions they are concerned with as European 
matters-of-concern, underlies the building of a Europe of patients. As described 
above, this process relies on, and contributes to the development of national 
patients’ organizations. The EPOs we studied are of grass-root origin: in 
contrast to Warleigh’s (2000) portrayal of European CSOs as often ‘elite-driven 
rather than membership-led’, representatives of national member organizations 
proactively engage in the building and running of EPOs. Conversely, EPOs 
contribute to the structuring of national patients’ organizations, and impact 
therefore on the vitality of domestic patient advocacy. This intermingling of 
European and national level of patient advocacy stands as one remarkable 
feature of the Europe of ‘patients-sufferers’. It pertains to the fact that 
healthcare still is the preserve of Member States and, consequently, that 
engaging the EU in healthcare policies cannot be done without close 
cooperation and negotiation between EPOs and their national member 
                                            
13 Knowing Me, Knowing You: Diagnosis and Early Intervention, undated: 21. 
14 We extend Laurent’s (2012) perspective on the European regulation of nano-objects, by 
considering Europeanization as an ontological construction of subjects and objects, e.g. of 
entities that have to be generated as relevant and do-able for Europe. 
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organizations. We will see more about this multilevel action and the tensions it 
sometimes generates in the next section. 
Moving from the national to the European level raises a specific 
representational concern: how to speak on behalf of individual patients who are 
dispersed across different countries, and whose experiences are embedded in 
diverse national contexts? This preoccupation with representation is critical for 
all CSOs’ identity and legitimacy: as Lahusen puts it (2004: 67), they have to 
avoid a situation where their professional advocates become insulated in the 
‘cocktail circuits of the Brussels polity’, and decoupled from their grassroots 
constituencies whose interests they claim to represent. EPOs may also face 
similar criticisms, some patients regarding them as ‘qua-institutions, far away in 
Brussels’15. As an organizational and a political answer to this challenge, EPOs 
seek to enroll individual patients in a variety of ways: EURORDIS offers them 
full-membership if they wish; ADHD Europe has long mobilized individual 
families, and still does via its member organizations; even Alzheimer Europe, 
which has no direct contact with individual constituencies of its member 
organizations, nevertheless publishes individual patients’ and carers’ 
testimonies on its website, portraying them as the ultimate beneficiaries of its 
actions. For EPOs, bringing individual patients to the fore, constantly recalling 
that their experiences matter, are at the core of their politics for transforming 
‘patients-sufferers’ into European individuals. 
A final significant characteristic of the EPOs we studied is that they all have 
members in non-European Member States, including associate members 
                                            
15 Interview with the vice-president of a small French rare disease patients’ group. 
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outside the European continent. At the very least, it is fair to say that EPOs 
picture the Europe of patients as part and parcel of international networks of 
patients, contributing therefore to the globalization of patient advocacy. 
2. European patients’ organizations and the shaping of a Europe for 
patients: elaborating evidence on the relevance and legitimacy of EU 
health policies 
The EPOs we studied seek to promote health policies and strategies in their 
condition-areas. To achieve this, they clearly endorse a position of ‘insiders’ 
rather than ‘outsiders’ (Della Porta and Caiani 2007; Greer et al. 2008) in the 
European political game and polity. This manifests in two ways. 
Firstly, they position themselves within the complex and sometimes 
confrontational European CSOs ecology to defend their causes against other 
interest groups, as demonstrated by the long-standing controversies 
surrounding EU law on the patenting of biotechnological inventions. European 
patients’ and environmental organizations first clashed on the issue in the late 
1990s. In opposition to many European environmental CSOs, the European 
Alliance of Genetic Support Groups – with which EURORDIS has many ties –  
was a prominent and seemingly influential force in lobbying efforts endorsing 
the EU’s 1998 Directive on the legal protection of biotechnological inventions 
(Balanya et al. 2000; Smyth 1997). The Directive sought to provide legal 
protection deemed essential for both techno-scientific research and economic 
development, but also to ensure that certain inventions remained ‘unpatentable 
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where their exploitation would be contrary to public policy or morality16’. Using 
for the first time its veto powers, the European Parliament rejected the draft 
Directive in 1995, but subsequently adopted it in 1997. During the 1997 vote, 
the halls of the European Parliament were filled with members of patient interest 
groups, wearing T-Shirts saying ‘No Patents, No Cures’, and ‘Patents for Life’. 
Fights and debates do not only oppose divergent vested interests; they also 
question the very nature of the European project, notably how and to what 
extent the ‘Europe of markets’ and its techno-economic agenda can 
accommodate a ‘social Europe’?  
Secondly, EPOs contribute to the elaboration and implementation of 
collective actions, associating European institutions, national patients’ 
organizations, European and national stakeholders in their condition-areas, 
namely consortia of researchers, clinicians, health professionals, and 
sometimes pharmaceutical and biotech firms. Additionally, they contribute to 
promoting the idea that there is a confluence of interests of these ‘partners’. 
This is very much in line with the EU’s multilevel soft modes of governance that 
were given a new impetus by the European Commission’s 2001 White Paper on 
European Governance (Borras and Conzelmann 2007). The EPOs have 
progressively become experts and major players in this new EU governance, 
looking to ways whereby the EU can be brought into the sector of health that 
remains the preserve of Member States. 
                                            
16 See http://europa.eu/legislation_summaries/internal_market/single_market_for_goods/pharm
aceutical_and_cosmetic_products/l26026_en.htm 
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These CSO interventions in the EU polity raise many concerns. Some 
scholars consider CSOs which play the EU multilevel governance game as just 
stakeholders among other stakeholders (Dunkerley and Fudge 2004; Della 
Porta and Caiani 2009), mostly engaged with the ‘participatory engineering’ that 
some critics allege characterizes the EU’s approach to collaboration with CSOs, 
in which it tends to ‘instrumentalize’ them as service providers and co-producers 
of regulatory policy (Borzel and Buzogany 2010). Others warn against the 
depoliticization potential of the EU multilevel governance, picturing it as a 
version of democracy mostly preoccupied with ‘problem-solving efficiency’, with 
‘output’ rather than ‘input-oriented legitimacy’ (Scharpf 1999; Mair 2005).  
In what follows, we examine how these debates on ‘Europe of markets’ 
versus ‘social Europe’ on the one hand, and on the democratic promises of EU 
multilevel governance on the other hand, surface in the EPOs’ 
pronouncements. More significantly, we investigate how they tackle these 
issues and contribute to their reframing through the concrete actions they 
undertake. 
The EPOs we studied are engaged in a series of actions which aim at 
ensuring the development of medical research and care services, and access to 
diagnosis, medications and care for all concerned European patients. Looking 
at their projects and pronouncements, one is struck by their intensive work in 
staging, comparing, confronting, and circulating data, facts, and statistics on 
cure and care across European countries. Barry (2001) analyzed in great detail 
the importance of measurements in the construction of Europe: as a matter of 
 18
fact, this metrological work aims at proving evidence on the relevance and 
legitimacy of healthcare issues at European level. EPOs regularly conduct 
surveys of their members for collecting data on their needs and expectations, as 
well as information on the provision of care in their countries. It is through this 
‘evidence-based activism’ that broader concerns with the neoliberal European 
project and with the deficit of democracy in Europe unfold in EPOs’ discourses 
and actions. 
2.1. Alzheimer Europe: soft modes of governance and hard facts to establish 
dementia as a EU priority  
At Alzheimer Europe’s 2006 annual conference held in Paris a ‘Declaration on 
the political priorities of the European Alzheimer Movement’17 was adopted. 
This ‘Paris Declaration’ called for dementia to be made a European and 
Member State public health priority and identified the four areas of promoting 
greater awareness and early diagnosis of the disease, greater coordination of 
research, sharing of best practices in dementia care, and advancing the rights 
of people diagnosed with dementia. 
Three years later in 2009 the European Commission issued a 
Communication18 to the European Parliament and Council on a European 
                                            
17 See http://www.alzheimer-europe.org/EN/Policy-in-Practice2/Paris-Declaration  
18 A Communication is an official document issued by the European Commission for advocating 
the EU support to initiatives it deems strategic. Such initiatives are prepared by the relevant 
General Directorates and/or EU working groups, in collaboration with various stakeholders. In 
contrast to hard law instruments, a Communication is not mandatory. However, it provides a 
crucial political impetus to areas like healthcare in which the EU has no regulatory 
competencies. A Communication is targeted to EU committees and political institutions, namely 
the European Council, and since 2009, the European Parliament too (a 2009 EU ruling requires 
the co-decision of the European Council and the European Parliament). After being examined 
by these institutions, a Communication may turn into a Recommendation by the European 
Council, and may sometimes result in the drafting of a Directive.  
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initiative on Alzheimer’s disease and other dementias. This was welcomed 
wholeheartedly by Alzheimer Europe, because it encompassed the priorities of 
the ‘Paris Declaration’. In the organization’s formal response to the 
Communication, it endorsed the soft law role of the EU as an empowerer, 
encourager and supporter of Member States, and advocated the use of the 
specific modes of the OMC, Joint Programming and public-private partnerships 
for securing official recognition of dementia as a European public health policy. 
Furthermore, indicating the organization’s eagerness to continue its active 
involvement in such European modes of dementia governance, it asserted its 
own epistemic and democratic credentials, emphasizing that it provides ‘robust 
and up-to-date information, engaging its member associations at grass-root 
level and facilitating the dissemination of the information’. 
The strategic importance attached by the organization to its metrological 
work and mobilization of research evidence was emphasized during a 2011 
conference presentation by Alzheimer Europe’s Executive Director in which he 
outlined various studies undertaken by the organization in ‘building a case for 
political action’19. One example of a study undertaken by the organization 
between 2006 and 2008 was partly funded by DG SANCO; this study, called 
EuroCoDe (European Collaboration on Dementia), sought, amongst other 
things, to develop ‘consensual indicators’ on prevalence rates and guidelines 
for diagnosis and treatment. Indeed, the EU institutions have conferred 
epistemic authority to Alzheimer Europe. The European Commission’s 2009 
Communication on AD and other dementias extensively cited research 
                                            
19 Jean Georges, ‘Dementia policy and planning in Europe – the NGO perspective’, presentation 
at Shared Priorities. The Dementia Agenda in Europe and Ireland, 17 June 2011, Dublin.  
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evidence produced by Alzheimer Europe, such as its comparative analysis of 
legislation in Europe relating to the rights of people with dementia, and facts 
circulated in its Dementia in Europe Yearbook, a publication of the organization 
since 2006 that receives financial support from the European Commission. As 
noted by the chairperson of the European Alzheimer’s Alliance in a foreword to 
the 2008 Yearbook, the annual publications ‘have proved valuable tools for 
policy makers to compare the state of dementia care in their country to other 
European countries and I am convinced that this type of exchange of good 
practices can contribute to an improvement in the lives of the 6.1 million people 
with dementia across the European Union’. (Alzheimer Europe, 2008: 12) 
 In December 2010 the European Parliament issued its Report on a 
European initiative on Alzheimer’s disease and other dementias. This official 
document too includes multiple references to facts about dementia produced by 
Alzheimer Europe, but also calls for official recognition of Alzheimer patients’ 
organizations as ‘prime partners’ of the EU and recommends that EU 
institutions should consider providing regular core funding to Alzheimer Europe 
and encourage Member States to do likewise for national Alzheimer 
organizations. Interestingly, when asked about the significance of the European 
Parliament’s different political groups within the European Alzheimer’s Alliance, 
one MEP who is the vice chair and a founding member of the Alliance said that 
‘It’s very much a consensus’20. 
At the very least, one can reasonably argue that through its production and 
circulation of original facts and figures about AD, Alzheimer Europe has fueled 
                                            
20 Interview on 8 April 2011. 
 21
the EU soft modes of governance with evidence that has contributed to making 
the disease a non-partisan, regular and do-able object of EU policy-making.  
2.2. EURORDIS: producing figures to align the ‘Europe of markets’ and a ‘social 
Europe’ in the area of rare diseases 
Rare diseases too are becoming a regular EU health priority. EURORDIS first 
action was to promote a European Regulation on Orphan Drugs. This was 
published in 199921, two years after EURORDIS inception. From the end of 
2000s onwards, EURORDIS has moved to another mission: motivating a global 
strategy on rare diseases in Europe, i.e. in all EU Member States, and in all 
areas that may contribute to the war on rare diseases, from research, clinical 
practices, health and social care, to medications. 
The rationale for this mission, and discussion it raised, offer a telling 
illustration of the tension between the ‘Europe of markets’ and a ‘social Europe’. 
Rare diseases posed particular challenges to the market, and this was why 
EURORDIS pushed for a specific regulation on orphan drugs to be issued. 
However, it was still necessary to ensure that all patients who needed those 
medicines had access to them. Some members of EURORDIS considered the 
European Directive on patients’ rights to cross-border healthcare as one 
solution to this problem. However, other representatives of national patients’ 
organizations and national stakeholders involved in the area of rare diseases 
strongly criticized this ‘rights’ option, which still vehicles, in their opinion, a 
neoliberal approach to the issue that they considered non efficient from an 
                                            
21 Regulation (EC) n° 141/2000 of the European Parliament and of the Council 16 December 
1999 on orphan medicinal products, Official Journal of the European Union, 3.7.2009: C 151/7. 
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economic point of view, and unacceptable from a human point of view. The risk, 
they said, was that medical and health ‘deserts’ might appear in certain 
countries and regions if cure and care were available elsewhere. This warning 
helped EURORDIS to put an even stronger focus on what it saw as the critical 
problem: before accessing medications, patients must be identified, diagnosed 
and monitored.  
EURORDIS began to lobby DG SANCO in the mid- 2000s, which, in 2007, 
started to consider the need for, and relevance of a global European strategy 
on rare diseases. On 9 June 2009, a Recommendation by the European 
Council of Ministers proposed that all Member States define and implement a 
national plan or strategy on rare diseases by 2013. This launched the 
EUROPLAN project. EURORDIS was then in charge of promoting the project at 
national level, in collaboration with National Alliances on Rare Diseases, and of 
following up its implementation. Moreover, at each and every step of this 
process, EURORDIS produced and disseminated facts and figures to advocate 
the need for a ‘social Europe’ if rare diseases patients are to be fully recognized 
by ordinary health and social systems. The following example offers a telling 
illustration. 
Initially, DG SANCO launched a vast consultation, announced at the 4th 
European Conference on Rare Diseases on 27 November 2007 in Lisbon. 
Hundreds of stakeholders from across Europe were then invited, throughout 
2008, to take stock of access to diagnosis, medication and care in their 
countries. EURORDIS played a decisive role in this consultation. It conducted a 
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survey of its members, called EurordisCare1, to collect data on experiences and 
expectations of patients and their organizations with regard to diagnosis and 
access to health services. Similar surveys have been repeated twice. The 
figures produced by EURORDIS allowed for cross-national comparison of 
health services, which was considered as truly added value of the EPO by EU 
and national authorities. It was on the basis of the results of this consultation 
that DG SANCO motivated the publication of a Communication by the European 
Commission, which was later turned into the above-mentioned 
Recommendation by the European Council of Ministers. 
The EurordisCare surveys illuminate how the EPO accommodates the 
‘Europe of markets’ and a ‘social Europe’ for advancing its cause. It produces 
evidence on the need for medical and social provision for patients’ rights to be 
recognized, and for the market to operate. Indeed, in the area of rare diseases, 
the market cannot develop efficiently if patients are still out of the reach of 
health and social systems. By producing facts and figures on the extent of this 
‘out of reach’ phenomenon, EURORDIS contributes to aligning the 
requirements of the market and the social needs of patients and families. 
2.3. ADHD Europe: combining ‘rights’ talk and scientific evidence 
Like Alzheimer Europe and EURODIS, ADHD Europe aims at developing cure 
and care for all European patients with the disorder. But unlike Alzheimer’s 
disease and rare diseases, ADHD is still a contested condition in certain 
countries, which induces much more hesitation on the appropriate route for 
promoting a EU policy on the disorder. 
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These tensions surface in ADHD Europe’ s own reflections on what ADHD is, 
and what it is to live with the disorder. ADHD Europe defines ADHD as a 
neurodevelopmental disorder which has a significant genetic component. As it 
reported in one Knowing Me, Knowing You document22, this definition has been 
central to the organization’s promotion of ADHD as a legitimate condition. In 
other publications however, ADHD Europe describes ADHD as a disability. This 
is consistent with its mission: drawing on ‘rights’ talk, it states that its aims is ‘to 
advance the rights of, and advocate on every level throughout Europe for 
people affected by ADHD and co-morbid conditions in order to help them reach 
their full potential’23 
There are some tensions in this ‘rights’ talk, however. It is not obvious that 
the framing of ADHD as a disability is embraced by all national member 
organizations of ADHD Europe, and it is not clear whether the organization has 
attempted to build allegiances with disability groups or influence disability policy 
at European level. Instead, it became a member of Mental Health Europe. Its 
first key intervention was a contribution to the EC Green Paper on Mental 
Health in 2006. With the help of Mental Health Europe, the organization has 
also been participating in the DG SANCO meeting in the Commission on the 
European Pact for Mental Health since 2008. 
But ‘rights’ talk has another facet: the fight for equal access to medications 
and care for all European patients with the condition. Central to the formation of 
                                            
22 Knowing Me, Knowing You: Curriculum for Our Future, undated: 26 
23 http://www.adhdeurope.eu/adhd-europe/objectives.html. Accessed 24 January 2010. 
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ADHD Europe and its development is the construction of national divergences 
in practices around ADHD as problematic, and the statement of a need for 
standardization in diagnosis and treatment approaches. For this to be achieved, 
ADHD Europe has progressively recognized the need for credentialed 
knowledge, which recently manifested in the election of scientific advisors. 
ADHD Europe also contributes data through surveys on its members. The 
organization conducted a survey published in 2009, entitled ‘Diagnosis and 
Treatment of AD/HD in Europe: Differences, Problems, Progress’, revised and 
expanded in 2011. The 2009 survey was conducted by sending questionnaires 
to the different national organizations about issues such as who diagnoses 
ADHD, treatments available, and existence of national policies. It also included 
tabular information comparing prices of different medications across countries, 
and treatment availability. 
The surveys conducted by ADHD Europe contribute to reconciling a ‘rights’ 
talk and a medico-scientific framing of ADHD. Basic human rights talk alone is 
not enough to combat those who continue to deny the existence of the 
condition, like certain Italian anti-psychiatry groups for instance24. Data 
collected by ADHD Europe highlight different practices and create a picture of 
inequality that can be overcome only by a greater consensus on the diagnosis 
and the standardization of treatment strategies (Clark 2009), which ultimately 
imply a full recognition of ADHD as a serious disorder all over Europe. By 
combining equal opportunities talk and ‘evidence-based activism’, ADHD 
                                            
24 This issue emerged at the Annual General Meeting of the organization in 2009 (interview with 
ADHD Europe Board member, 13 October 2010). 
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Europe seeks to transform the abstract ‘patient-citizen’ favored by EU legal 
corpuses into an actual ‘patient-citizen-sufferer’. 
2.4. What Europe for patients do EPOs build? 
The examples of EPOs’ evidence-based activism described above illustrate that 
they are not simply lobbying for their interests; they are contributing data and 
statistics that also progressively map out health issues as economic, political 
and social concerns for Europe. Grounding a Europe for patients in facts, 
figures and statistics that allows cross-national comparison raises the question 
of commensurability between countries, and leads EPOs to balance between 
two options: standardization of health services versus diversification of 
solutions, according to the peculiarities of national health systems and specific 
desiderata of national organizations. The EUROPLAN project promoted by 
EURORDIS offers a telling example. One pivotal element of the plan was the 
organization of services for diagnosis, care and social support to patients with 
rare diseases. How to achieve this was a matter of intensive technical and 
political debates. Should centers of reference be created in every single 
country, or should networks of experts be set up across Europe so that ordinary 
medical consultations may call upon them in case they need assistance? This 
question points to major disparities between Member States: it is clear indeed 
that many countries do not have material and expert resources. Eventually, a 
mixed solution of national centers of expertise and European reference 
networks was decided upon. However, during a EURORDIS Membership 
Meeting entitled ‘The voice of rare diseases patients in national plans for rare 
diseases’ held in Amsterdam in May 2011, its Executive Director emphasized 
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the need for a sound evaluation of this option if the organization is to secure the 
national plans on the long run25. 
Linked to this issue of ‘standardization in a non-standard world’, to echo 
Epstein and Timmermans (2010), EPOs also contribute to the production of 
ideas about how ‘advanced’ or ‘backward’ various European countries are in 
respect of the recognition, authorization and provision for the various conditions 
or causes around which they mobilize. Significantly, these EPOs’ ‘development 
rankings’ vary across the conditions and do not conform with orthodoxies about 
which European countries are most and least modernized. For example, 
EURORDIS promotes the idea that France is ‘advanced’ and provides a model 
for the war on rare diseases, whereas for ADHD Europe, France is lagging 
behind. The designation of certain countries as models of best practice takes on 
a particular significance in the context of soft modes of governance such as the 
OMC, the aim of which is to promote the replication of those models in other 
Member States.  
A final remark is worth being stated: EPOs’ ‘evidence-based activism’, and 
the Europe for patients they build thereof, put a strong focus on the metrological 
shaping of Europe as an important means for addressing issues of social justice 
and health democracy. What is particularly interesting is that these issues 
unfold differently within each EPO. Our fieldwork suggests that EPOs articulate 
in various ways these social issues with a techno-scientific and economic 
agenda firmly grounded in a series of indicators and measurements. At the very 
                                            
25 Notes taken during the meeting. 
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least, this points to the variety of conceptions that EPOs have on the ‘Europe of 
markets’ and a ‘social Europe’. 
Conclusion 
Reflecting on the promises of Europeanization from below, Della Porta and 
Caiani (2009: 47) regret that ‘The EU is rarely targeted from below’; civil society 
actors seldom frame their object and issue scope as European and a national 
orientation of public debates and arenas continues to prevail. Our exploration of 
EPOs suggests otherwise: in the sector of health which still is the domain of 
prerogatives of Member States, EPOs which decide to ‘go to Europe’ cannot but 
construct a Europe of and for patients. Studying particular sectors such as the 
domain of health thus offers a fruitful locus for investigating the process of 
Europeanization from below and its effects on the shaping of European policies, 
and on the dynamics of national activism.  
One may argue that the politics that EPOs adopt, engaging them as ‘euro-
pragmatics’ (Mair, 2005) and as experts on various topics – ranging from 
European rulings and policy-making to the technicalities of national health 
systems –, contributes to the European project that some scholars depict as a 
technocratic one, based on a depoliticized democracy (Mair 2000; Storey 
2008). EPOs are certainly experts on their conditions and on the functioning of 
health institutions, but, and this adds a significant value to their actions, their 
expertise mobilizes concerned people’s experience and knowledge. As a 
consequence, it is fair to say that EPOs bring European concerned people and 
voice their preoccupations in various ways up to multiple European arenas. 
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Beyond this, our fieldwork allows us to argue that EPOs engage in the on-going 
construction of Europe, and that this is a highly political endeavor of the sort. 
The disputes that regularly oppose EPOs and EU environmentalists on the 
regulation of bio-products, the debates that EPOs raise at national and 
European level on the issue of health inequalities, and most importantly, the 
evidence that EPOs bring to the fore to support their arguments, have removed 
politics from a classic partisan fight to an extended multifaceted collective 
experimentation. Studying the construction of Europe as a collective 
experimentation opens a research perspective that is worthy of exploration. 
This being said, we must avoid romanticizing EPOs: they are particular civil 
society organizations, whose achievements must be appreciated in light of the 
efforts they put to impinge on the fabrics of Europe. This does not come without 
tensions and difficulties. As a matter of fact, the current financial and economic 
crisis that threatens the Euro-Zone and puts the EU governance under 
pressure, constitutes a serious obstacle for EPOs themselves, as witnessed by 
the adoption of the Portuguese Plan on Rare Diseases without financial support 
by the Portuguese government26. The EU agenda-setting and the budgeting of 
its priorities may well change the content and the scope of EPOs’ politics and 
expectations. 
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